Edition:
India

Vivus Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

5.15USD
21 Sep 2018
Change (% chg)

$-0.07 (-1.34%)
Prev Close
$5.22
Open
$5.21
Day's High
$5.25
Day's Low
$5.00
Volume
43,021
Avg. Vol
19,979
52-wk High
$10.05
52-wk Low
$3.33

Latest Key Developments (Source: Significant Developments)

Vivus Announces 1-For-10 Reverse Stock Split
Monday, 10 Sep 2018 

Sept 10 (Reuters) - Vivus Inc ::VIVUS ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.VIVUS INC - EFFECTIVE SEPTEMBER 10, 2018, COMPANY WILL ENACT A 1-FOR-10 REVERSE STOCK SPLIT.VIVUS INC - TICKER SYMBOL, VVUS, WILL REMAIN UNCHANGED.  Full Article

Vivus Announces Positive Results From A Phase 1 Clinical Trial Of VI-0106
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Vivus Inc ::VIVUS ANNOUNCES POSITIVE RESULTS FROM A PHASE 1 CLINICAL TRIAL OF VI-0106.VIVUS ANNOUNCES POSITIVE RESULTS FROM A PHASE 1 CLINICAL TRIAL OF VI-0106.VIVUS INC - INTENDS TO REQUEST BOTH FAST TRACK AND BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR VI-0106 AS TREATMENT OPTION FOR PAH PATIENTS.  Full Article

Vivus Says Met Closing Conditions Related To Co's Acquisition Of U.S. And Canadian Rights To Pancreaze
Monday, 11 Jun 2018 

June 11 (Reuters) - Vivus Inc ::VIVUS EXECUTES ON ITS STRATEGIC VISION WITH THE CLOSING OF ITS ACQUISITION OF PANCREAZE® AND PREVIOUSLY ANNOUNCED FINANCING TRANSACTION.VIVUS - MET CLOSING CONDITIONS RELATED TO CO'S PREVIOUSLY ANNOUNCED ACQUISITION OF U.S. AND CANADIAN RIGHTS TO PANCREAZE.  Full Article

Vivus Says Got Letter From Nasdaq Informing that it Granted Co's Request For Continued Listing, On Conditions
Friday, 18 May 2018 

May 18 (Reuters) - Vivus Inc ::VIVUS SAYS ON MAY 17, GOT LETTER FROM NASDAQ INFORMING NASDAQ HEARINGS PANEL GRANTED CO'S REQUEST FOR CONTINUED LISTING, ON CONDITIONS- SEC FILING.  Full Article

Vivus Reports Q1 Loss Per Share Of $0.10
Wednesday, 9 May 2018 

May 8 (Reuters) - Vivus Inc ::VIVUS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.VIVUS INC QTRLY TOTAL REVENUE $11.9 MILLION VERSUS $27 MILLION.VIVUS INC QTRLY LOSS PER SHARE $0.10.  Full Article

Vivus Says John Amos Appointed CEO
Tuesday, 1 May 2018 

April 30 (Reuters) - Vivus Inc ::VIVUS STRENGTHENS EXECUTIVE LEADERSHIP TEAM.SAYS JOHN AMOS APPOINTED CEO.SCOTT OEHRLEIN IS CHIEF OPERATIONS OFFICER, A NEWLY CREATED POSITION WITHIN COMPANY.KENNETH SUH WILL CONTINUE AS PRESIDENT AND CEO OF WILLOW BIOPHARMA INC., NOW A WHOLLY-OWNED SUBSIDIARY OF VIVUS.  Full Article

Vivus Announces Change In Leadership
Wednesday, 27 Dec 2017 

Dec 26 (Reuters) - Vivus Inc ::VIVUS ANNOUNCES CHANGE IN LEADERSHIP.VIVUS INC - BOARD MEMBER THOMAS B. KING APPOINTED INTERIM CEO.VIVUS INC - SETH FISCHER STEPS DOWN AS CEO EFFECTIVE DECEMBER 31, 2017.  Full Article

Vivus reports third quarter 2017 financial results
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Vivus Inc :Vivus reports third quarter 2017 financial results.Vivus Inc - ‍total revenue, net for third quarters of 2017 and 2016, was $15.2 million and $13.4 million, respectively​.Vivus Inc - qtrly ‍basic and diluted net loss per share $0.06​.  Full Article

Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra
Monday, 3 Oct 2016 

VIVUS Inc : VIVUS Inc says additionally, Metuchen will be responsible for royalties due to Mitsubishi Tanabe Pharma corporation based on net sales . VIVUS and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra .VIVUS-Signed commercial supply agreement pursuant to which Co to be responsible for manufacture, supply of Stendra to Metuchen; VIVUS received $70 million.  Full Article